摘要
目的观察罗沙司他治疗腹膜透析贫血的疗效及其对腹膜溶质转运能力变化的影响。方法纳入新疆医科大学第五附属医院和新疆维吾尔自治区人民医院2022年1月至2023年1月接受规律腹膜透析贫血的患者100例,随机分为试验组(55例)、对照组(45例),分别使用罗沙司他和促红素注射液治疗。比较治疗前后试验组和对照组的贫血指标、铁代谢指标、炎症指标、腹膜溶质转运能力。结果①治疗8周后,两组患者贫血情况均较治疗前改善(P<0.05)。试验组贫血治疗总有效率略高于对照组(87.04%vs.84.44%),但差异无统计学意义(P>0.05)。②两组患者血清铁蛋白均低于100μg/L,转铁状态蛋白饱和度均>20%,血清铁浓度均处于正常范围,治疗前以及治疗后组间比较差异均无统计学意义(P>0.05)。③治疗前后的C反应蛋白(CRP)中位数均处于正常范围内,但试验组治疗后水平增高,差异有统计学意义(P<0.05)。④两组患者腹膜溶质转运能力中位数水平较治疗前轻度增高(P<0.05),但两组患者腹膜转运能力比较,差异无统计学意义(P>0.05)。结论罗沙司他可以在轻微炎症状态下有效改善腹膜透析患者血红蛋白水平,轻度增加患者腹膜溶质转运能力。罗沙司他与促红素注射液纠正贫血能力和影响腹膜溶质转运能力方面作用相当。
Objective To observe the therapeutic effect of roxadustat on anemia in peritoneal dialysis and its influence on the changes of peritoneal solute transport capacity.Methods Totally 100 patients with anemia who received regular peritoneal dialysis in the Fifth Affiliated Hospital of Xinjiang Medical University and Xinjiang People's Hospital from January 2022 to January 2023 were enrolled and divided into experimental group(n=55)and control group(n=45)randomly,and the patients in the two groups were treated with roxadustat and erythropoiesis-stimulating agents respectively.Anemia indicators,iron metabolism indicators,inflammation indicators,and peritoneal solute transport capacity of patients in the two groups were compared before and after treatment.Results①After 8 weeks of treatment,the hemoglobin levels of patients in the two groups were significantly improved(P<0.05).The total effective rate of treatment for anemia in experimental group was slightly higher than that in control group(87.04%vs.84.44%),but there was no significant difference(P>0.05).②The serum ferritin of patients in the two groups was less than 100μg/L.The transferrin saturation was more than 20%.The concentration of serum iron was within the normal range,and there was no significant difference before and after treatment or between the two groups after treatment(P>0.05).③The median CRP before and after treatment was within the normal range,but the median CRP in experimental group increased after treatment(P<0.05).④The median of peritoneal solute transport capacity of the two groups slightly increased(P<0.05)after treatment,but there was no significant difference in peritoneal transport capacity between the two groups(P>0.05).Conclusion Roxadustat can effectively improve the hemoglobin level of peritoneal dialysis patients,and slightly increase the peritoneal solute transport capacity in mild inflammation.Roxadustat and erythropoiesis-stimulating agent injection have similar effects in correcting anemia and affecting peritoneal solute transport capacity.
作者
任荣
陈凯旋
贾依娜西·阿扎提
张静
曹冰
姜鸿
Ren Rong;Chen Kaixuan;Azati Jiayinaxi;Zhang Jing;Cao Bing;Jiang Hong(Department of Nephrology,the Fifth Affiliated Hospital of Xinjiang Medical University,Urumqi 830000,China;Xinjiang Medical University,Urumqi 830000,China;Department of Nephrology,Xinjiang People's Hospital,Urumqi 830000,China)
出处
《实用药物与临床》
CAS
2024年第4期260-264,共5页
Practical Pharmacy and Clinical Remedies
基金
新疆维吾尔自治区自然科学基金资助面上项目(2021D01C435)。
关键词
罗沙司他
肾性贫血
腹膜透析
腹膜转运功能
Roxadustat
Renal anemia
Peritoneal dialysis
Peritoneal transport function
作者简介
通信作者:姜鸿。
